Aldo Renault

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette et al. · Journal of Thoracic Oncology · 2019 · 182 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

Jean-Louis Pujol, A. Lavolé, Élisabeth Quoix et al. · Annals of Oncology · 2015 · 97 citations · Full text

Medicine, Oncology, Pharmacology +10

Customized Adjuvant Phase II Trial in Patients With Non–Small-Cell Lung Cancer: IFCT-0801 TASTE

Marie Wislez, Fabrice Barlési, Benjamin Besse et al. · Journal of Clinical Oncology · 2014 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier et al. · Journal of Clinical Medicine · 2020 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

K. Saboundji, J.B. Auliac, Maurice Pérol et al. · Targeted Oncology · 2018 · 43 citations

Medicine, Oncology, Pharmacology +16